Extramedullary Disease in Acute Promyelocytic Leukemia

All-transretinoic acid (ATRA) is currently recommended as standard treatment for acute promyelocytic leukemia (APL). However there has been increasing concern that ATRA is associated with unusual sites of relapse. Although there is insufficient evidence so far to substantiate this, we review the pot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 1999-01, Vol.33 (3-4), p.219-229
Hauptverfasser:	Evans, G. D., Grimwade, D. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	adhesion molecules Adult Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use APL ATRA Central Nervous System Neoplasms - physiopathology CNS leukemia extramedullary leukemia Female Humans Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - genetics Leukemia, Promyelocytic, Acute - physiopathology Male Middle Aged Recurrence Tretinoin - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	All-transretinoic acid (ATRA) is currently recommended as standard treatment for acute promyelocytic leukemia (APL). However there has been increasing concern that ATRA is associated with unusual sites of relapse. Although there is insufficient evidence so far to substantiate this, we review the potential mechanisms by which ATRA may increase the incidence of extramedullary and, in particular, central nervous system (CNS) relapse.
ISSN:	1042-8194 1029-2403
DOI:	10.3109/10428199909058422